During the past decade, Birmingham Hematology and Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 13 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Birmingham Hematology and Oncology" #1 sponsor was "US Oncology Research" with 5 trials, followed by "Eisai Inc." with 3 trials sponsored, "Novartis Pharmaceuticals" with 3 trials sponsored, "Agennix" with 2 trials sponsored and "Alaunos Therapeutics" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Birmingham Hematology and Oncology" #1 collaborator was "Sanofi" with 4 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "US Oncology Research" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Eisai Limited" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Birmingham Hematology and Oncology" are "Breast Cancer" (6 trials), "Metastatic Breast Cancer" (3 trials), "Prostate Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Birmingham Hematology and Oncology" in a lesser frequency.

Most popular intervention types in "Birmingham Hematology and Oncology" are "Drug" (29 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Cyclophosphamide" (2 trials), "Docetaxel" (2 trials), "Doxorubicin" (2 trials) and "Prednisone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Birmingham Hematology and Oncology" are 17 trials for "All" genders, 7 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Birmingham Hematology and Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Birmingham Hematology and Oncology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Birmingham Hematology and Oncology, 0 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".